What’s New

RNS60 Shows Promise as an Inhaled Therapy in a Mouse Model of Multiple Sclerosis
The findings of a collaborative project between researchers at Rush University in Chicago and Revalesio were published in the journal Neurochemical Research. An earlier study by the same group had...
Read more
FDA Allows Revalesio's Investigational New Drug Application to Study RNS60 in ALS
Revalesio received US Food and Drug Administration (FDA) allowance of an Investigational New Drug (IND) application for Phase II clinical testing of RNS60 in patients with amyotrophic lateral sclerosis (ALS)....
Read more